HER2-negative negative breast cancer means that the cancerous cells do not contain high levels of the protein HER2. Cancer cells that are HER2 negative may grow more slowly and are less likely to recur (come back) or spread to other parts of the body than cancer cells that have a large amount of HER2 on their surface. Hormonal therapy is considered the standard initial treatment for HER2-negative metastatic breast cancer that is also hormone receptor-positive.
Market Dynamics:
Rise in burden of breast cancer, increase in number of clinical trials, increase in demand for safe and effective treatment, and rise in focus on the development of novel drugs or therapies are major factors expected to drive growth of the global HER-2 negative breast cancer market.
For instance, in September 2022, Novartis announced results from a pooled exploratory analysis across the entire MONALEESA Phase 3 program, confirming nearly one year of additional overall survival benefit in a subgroup of patients with aggressive forms of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook